.png){kind=icon}
.png){kind=icon}
Return
Linker-directed lipid-antigen conjugates co-enhance lymph node targeting and antigen presentation for potent T cell immunity
.png){kind=icon}
OA
AI
J
L
C
J
Y
W
L
Z
DOI：10.1016/j.mtbio.2026.103505.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The clinical efficacy of peptide-based cancer vaccines is limited by inefficient lymphatic delivery and suboptimal antigen presentation. Here, we report a rationally engineered class of lipid-antigen conjugates that co-enhance lymph node (LN) targeting and antigen-presenting cell (APC) uptake through molecular-level structural optimization. By systematically varying lipid tail composition and linker chemistry, we identify a lead construct (dOA-K-O) incorporating a dioleic acid (dOA) lipid tail and an L-lysine (K) linker, which outperforms the clinically used DSPE-PEG2000 conjugate (DSPE-O). Mechanistically, the positively charged L-lysine linker promotes albumin binding while reducing excessive self-assembly, enhancing lymphatic trafficking and facilitating APC internalization. In vivo, dOA-K-O elicits robust antigen cross-presentation and induces an 8-fold increase in antigen-specific CD8+ T cell responses compared to unmodified antigenic peptide and 3-fold higher than DSPE-O. This enhanced cellular immunity translates into marked tumor suppression in both prophylactic and therapeutic B16-OVA melanoma models. Our results establish a design paradigm in which linker chemistry and lipid tail composition are synergistically optimized to boost the immunogenicity of peptide vaccines for cancer immunotherapy, which may provide a chemical and structural basis for the optimization of peptide-based vaccine delivery systems.
Keywords:
Lipid-antigen conjugates
Lymph node targeting
Vaccine delivery
Cellular immunity
Albumin hitchhiking
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.2
Papers:
3.6K
Citations:
9.5K
Organization
Cited Papers